Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $204,725 | 34 | 67.7% |
| Honoraria | $75,000 | 13 | 24.8% |
| Travel and Lodging | $21,351 | 17 | 7.1% |
| Food and Beverage | $662.92 | 8 | 0.2% |
| Unspecified | $650.00 | 3 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $107,409 | 17 | $0 (2023) |
| CSL Behring | $92,576 | 29 | $0 (2021) |
| PFIZER INC. | $90,123 | 22 | $0 (2022) |
| The Medicines Company | $11,616 | 3 | $0 (2018) |
| Novo Nordisk AS | $650.00 | 3 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $15.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $12,785 | 1 | Daiichi Sankyo Inc. ($12,785) |
| 2022 | $11,062 | 3 | Daiichi Sankyo Inc. ($8,062) |
| 2021 | $30,448 | 11 | CSL Behring ($15,000) |
| 2020 | $54,131 | 12 | Daiichi Sankyo Inc. ($36,631) |
| 2019 | $70,851 | 20 | Daiichi Sankyo Inc. ($38,133) |
| 2018 | $51,010 | 9 | PFIZER INC. ($34,775) |
| 2017 | $72,103 | 19 | PFIZER INC. ($42,217) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2023 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $12,785.30 | General |
| 09/05/2022 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 02/22/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $4,326.00 | General |
| 02/22/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,736.00 | General |
| 10/18/2021 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 06/24/2021 | Daiichi Sankyo Inc. | SAVAYSA (Drug) | Consulting Fee | Cash or cash equivalent | $4,326.00 | General |
| Category: Thrombosis | ||||||
| 06/23/2021 | CSL Behring | — | Honoraria | Cash or cash equivalent | $5,000.00 | General |
| 06/22/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,180.00 | General |
| 06/17/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 05/21/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 04/06/2021 | CSL Behring | — | Honoraria | Cash or cash equivalent | $5,000.00 | General |
| 01/28/2021 | Daiichi Sankyo Inc. | SAVAYSA (Drug) | Consulting Fee | Cash or cash equivalent | $5,506.00 | General |
| Category: Thrombosis | ||||||
| 01/28/2021 | Daiichi Sankyo Inc. | SAVAYSA (Drug) | Consulting Fee | Cash or cash equivalent | $786.00 | General |
| Category: Thrombosis | ||||||
| 01/21/2021 | Novo Nordisk AS | RYBELSUS (Drug) | — | Cash or cash equivalent | $400.00 | Research |
| Study: NN9924-4309 • Category: Diabetes | ||||||
| 01/04/2021 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 10/26/2020 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 10/22/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,933.00 | General |
| 10/20/2020 | CSL Behring | — | Honoraria | Cash or cash equivalent | $5,000.00 | General |
| 10/20/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,180.00 | General |
| 10/20/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,180.00 | General |
| 07/13/2020 | CSL Behring | — | Honoraria | Cash or cash equivalent | $5,000.00 | General |
| 05/26/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,933.00 | General |
| 05/26/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,345.00 | General |
| 05/26/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,573.00 | General |
| 04/30/2020 | CSL Behring | — | Honoraria | Cash or cash equivalent | $5,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9924-4309 | Novo Nordisk AS | $650.00 | 3 |
About Dr. David Waters, MD
Dr. David Waters, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508808122.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Waters, MD has received a total of $302,389 in payments from pharmaceutical and medical device companies, with $12,785 received in 2023. These payments were reported across 75 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($204,725).
Practice Information
- Specialty Internal Medicine
- Other Specialties Cardiovascular Disease
- Location San Francisco, CA
- Active Since 06/11/2006
- Last Updated 09/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508808122
Products in Payments
- LIPITOR (Drug) $59,623
- Multiple Products (Biological) $24,471
- SAVAYSA (Drug) $10,618
- RYBELSUS (Drug) $650.00
- PRALUENT (Drug) $15.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736